NDC product
Lidocaine Hydrochloride and Hydrocortisone Acetate
NDC 13925-164 · Seton Pharmaceuticals
Key facts
| Product NDC | 13925-164 |
|---|---|
| Proprietary name | Lidocaine Hydrochloride and Hydrocortisone Acetate |
| Nonproprietary name | Lidocaine Hydrochloride and Hydrocortisone Acetate |
| Substances | LIDOCAINE HYDROCHLORIDE, HYDROCORTISONE ACETATE |
| Dosage form | GEL |
| Route | RECTAL |
| Labeler | Seton Pharmaceuticals |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | UNAPPROVED DRUG OTHER |
| Pharmacologic classes | Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Local Anesthesia [PE] |
| Marketing start | Jun 17, 2011 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: